Logo image
Cerebrospinal fluid liquid biopsy by low-pass whole genome sequencing for clinical disease monitoring in pediatric embryonal tumors
Journal article   Open access   Peer reviewed

Cerebrospinal fluid liquid biopsy by low-pass whole genome sequencing for clinical disease monitoring in pediatric embryonal tumors

Erin E. Crotty, Vera A. Paulson, Rebecca Ronsley, Nicholas A. Vitanza, Amy Lee, Jason Hauptman, Hannah E. Goldstein, Christina M. Lockwood, Sarah E. S. Leary and Bonnie L. Cole
Neuro-Oncology Advances, Vol.6(1)
2024

Abstract

circulating free DNA adolescent Article atypical teratoid rhabdoid tumor central nervous system tumor cerebrospinal fluid child childhood cancer clinical article cohort analysis controlled study cytopathology demographics disease surveillance embryonal tumor female gene gene amplification human human tissue liquid biopsy male medulloblastoma minimal residual disease monosomy mycn gene nuclear magnetic resonance imaging pilot study primary tumor prospective study whole genome sequencing
Background: Liquid biopsy assays that detect cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) are a promising tool for disease monitoring in pediatric patients with primary central nervous system (CNS) tumors. As a compliment to tissue-derived molecular analyses, CSF liquid biopsy has the potential to transform risk stratification, prognostication, and precision medicine approaches. Methods: In this pilot study, we evaluated a clinical pipeline to determine feasibility and sensitivity of low-pass whole genome sequencing (LP-WGS) of CSF-derived cfDNA from patients with CNS embryonal tumors. Thirty-two longitudinal CSF samples collected from 17 patients with molecularly characterized medulloblastoma (12), embryonal tumor with multilayered rosettes (2), CNS embryonal tumor, not elsewhere classified (NEC) (2), and atypical teratoid/rhabdoid tumor (1) were analyzed. Results: Adequate CSF-derived cfDNA for LP-WGS analysis was obtained in 94% of samples (30/32). Copy number variants compatible with neoplasia were detected in 90% (27/30) and included key alterations, such as isodicentric ch17, monosomy 6, and MYCN amplification, among others. Compared to tissue specimens, LP-WGS detected additional aberrations in CSF not previously identified in corresponding primary tumor specimens, suggesting a more comprehensive profile of tumor heterogeneity or evolution of cfDNA profiles over time. Among the 12 CSF samples obtained at initial staging, only 2 (17%) were cytologically positive, compared to 11 (92%) that were copy number positive by LP-WGS. Conclusions: LP-WGS of CSF-derived cfDNA is feasible using a clinical platform, with greater sensitivity for tumor detection compared to conventional CSF cytologic analysis at initial staging. Large prospective studies are needed to further evaluate LP-WGS as a predictive biomarker. © 2024 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
url
https://doi.org/10.1093/noajnl/vdae126View
Published (Version of record) Open

Metrics

4 Record Views

Details

Logo image